Date published: 2025-11-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

MBNL2 Inhibitors

Muscleblind-like 2 (MBNL2) is a vital RNA-binding protein that plays a significant role in regulating alternative splicing in the context of various biological processes. Alternative splicing is a crucial mechanism that allows a single gene to generate multiple mRNA isoforms, ultimately leading to the production of distinct protein variants with diverse functions. MBNL2, a member of the Muscleblind-like (MBNL) family, is primarily known for its involvement in the regulation of splicing events in muscle tissues. It exerts its influence by binding to specific RNA motifs, such as CUG and CCUG repeats, commonly found in the untranslated regions of mRNA transcripts. Functionally, MBNL2 acts as a key player in the maintenance of proper muscle function and development. It accomplishes this by overseeing the splicing of critical muscle-related genes, ensuring the production of functional proteins. Dysregulation or inhibition of MBNL2 can lead to aberrant alternative splicing patterns, resulting in the misexpression of muscle-related genes. Inhibition of MBNL2 is a complex process that can have profound effects on alternative splicing patterns and, consequently, protein expression in muscle tissues. While the focus of research involving MBNL2 has largely revolved around its misregulation in diseases like myotonic dystrophy, inhibiting MBNL2 is not a typical objective due to its essential role in maintaining proper splicing patterns in muscle-related genes. However, it is important to recognize that in pathological conditions where MBNL2 is sequestered or rendered inactive, the result is an uncontrolled misregulation of splicing events. Therefore, understanding the mechanisms that lead to the inhibition of MBNL2, such as sequestration by repeat-containing RNA, is crucial for unraveling the pathophysiology of diseases associated with splicing defects. In summary, MBNL2 is a critical RNA-binding protein with a central role in regulating alternative splicing in muscle tissues, and its inhibition, though not a common goal, is a topic of interest in the context of neuromuscular diseases.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

Platinum-based chemotherapy drug that forms DNA adducts, leading to DNA damage and cell cycle arrest. It can indirectly affect MBNL2 by inducing stress response pathways that can modulate its expression or activity.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Histone deacetylase (HDAC) inhibitor that increases histone acetylation, leading to altered gene expression. It can indirectly influence MBNL2 expression and function through its impact on chromatin structure and gene regulation.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Antibiotic that intercalates into DNA, inhibiting RNA polymerase activity and transcription. Its disruption of transcriptional processes can indirectly affect MBNL2 expression or function.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Phosphatidylinositol 3-kinase (PI3K) inhibitor that blocks downstream signaling in the PI3K/AKT pathway. This pathway is involved in various cellular processes, and its modulation can indirectly influence MBNL2 activity.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$36.00
$149.00
11
(1)

Pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. Its impact on cellular processes can indirectly affect MBNL2 expression or function.

Lovastatin

75330-75-5sc-200850
sc-200850A
sc-200850B
5 mg
25 mg
100 mg
$28.00
$88.00
$332.00
12
(1)

HMG-CoA reductase inhibitor that reduces cholesterol synthesis. It can indirectly modulate MBNL2 through its influence on prenylation and the mevalonate pathway, which may affect MBNL2 localization or function.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

p38 MAPK inhibitor that blocks p38 MAPK signaling. This kinase pathway is involved in various cellular processes, and its modulation can indirectly influence MBNL2 activity.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

mTOR inhibitor that blocks mTOR signaling, a pathway involved in cell growth and protein synthesis. Its modulation can indirectly impact MBNL2 activity through downstream effects on cellular processes.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

MEK1/2 inhibitor that blocks the MAPK/ERK pathway. This pathway influences gene expression and various cellular processes, indirectly affecting MBNL2 expression or function.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

JNK inhibitor that blocks JNK signaling. The JNK pathway is involved in stress response and apoptosis, and its modulation can indirectly influence MBNL2 activity through downstream effects on cellular processes.